The investigation by Levi & Korsinsky into potential securities law violations is likely to negatively impact Vertex Pharmaceuticals' stock price in the short term. The disappointing results from the RewinD-LB Phase 2b clinical trial for suzetrigine add to the negative sentiment, as investors may be concerned about the company's future prospects and legal challenges.